文献速递泌尿男性生殖肿瘤

根治性前列腺切除术后立体定向调强放疗的患者报告结局:一项非随机临床试验

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项2期单臂非随机临床试验在美国2个学术中心纳入100例根治性前列腺切除术后生化复发或不良病理特征的患者,给予前列腺床30至34 Gy分5次立体定向体部放疗(SBRT),并与200例术后常规分割放疗(CFRT)队列比较2年患者报告结局。SBRT耐受性良好,尿失禁、尿路刺激和肠道功能减退超过2倍最小临床重要差异阈值的比例分别为38.9%、17.9%和34.1%,与CFRT相比调整比值比均无统计学显著差异。作者认为随机研究和更长随访将更好地定义术后SBRT的毒性和疗效特征。

要点

  • 术后SBRT组晚期2级和3级泌尿生殖毒性累积发生率分别为25%和4%。
  • 术后SBRT组晚期2级和3级胃肠道毒性累积发生率均为3%。
  • 与CFRT队列相比,SBRT组尿失禁、尿路刺激和肠道功能减退的调整比值比均无统计学显著差异。

核心结论

  • 在这项非随机临床试验中,根治性前列腺切除术后SBRT耐受性良好,2年内泌尿或肠道患者报告结局与CFRT相比无 measurable 差异。
  • 作者认为随机研究和更长随访将更好地定义术后SBRT的毒性和疗效特征。

研究设计与样本

  • 这项2期单臂非随机临床试验在美国2个学术中心开展,并纳入一个对照队列。
  • 纳入标准为根治性前列腺切除术后前列腺特异性抗原大于0.03 ng/mL或具有不良病理特征。
  • 数据收集时间为2018年2月至2021年3月,数据分析时间为2024年1月至10月。
  • 干预为前列腺床SBRT 30至34 Gy分5次;淋巴结照射、大体病灶推量及内分泌治疗由医生酌情决定。
  • SBRT组100例,中位(IQR)年龄68.5(63.9-71.4)岁,中位(IQR)随访43(37-53)个月;对照队列为200例接受术后CFRT的患者。

主要发现

  • SBRT组晚期2级和3级泌尿生殖毒性累积发生率分别为25%和4%,晚期2级和3级胃肠道毒性累积发生率分别为3%和3%。
  • SBRT组患者报告结局减退超过2倍MCID的比例为:尿失禁38.9%(37/95)、尿路刺激17.9%(17/95)、肠道功能34.1%(31/91)。
  • 与CFRT队列相比,SBRT组尿失禁减退超过2倍MCID的调整比值比为1.55(95%CI 0.87-2.76;P=0.14)。
  • 与CFRT队列相比,SBRT组尿路刺激减退超过2倍MCID的调整比值比为0.94(95%CI 0.46-1.94;P=0.87)。
  • 与CFRT队列相比,SBRT组肠道功能减退超过2倍MCID的调整比值比为1.03(95%CI 0.57-1.84;P=0.93)。

关键数值与推荐

  • 晚期毒性定义为治疗结束后超过90天,按不良事件通用术语标准4.03版分级。
  • 患者报告结局采用扩展前列腺癌指数-26(EPIC-26)测量。
  • 评价指标为治疗前2年内任何时间点患者报告结局减退超过最小临床重要差异(MCID)阈值2倍的比例。
  • 纵向患者报告结局比较采用逻辑回归,并调整基线评分、年龄及是否接受淋巴结照射。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出为非随机临床试验。
  • 原文指出作者认为随机研究和更长随访将更好地定义术后SBRT的毒性和疗效特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Postoperative radiotherapy remains underused for men with biochemical recurrence or adverse pathological features after radical prostatectomy (RP). Stereotactic body radiotherapy (SBRT) may improve utilization and poses potential radiobiological advantages. OBJECTIVE: To evaluate physician-reported late toxic effects and 2-year patient-reported outcomes (PROs) following post-RP SBRT. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, single-arm trial was conducted in 2 academic centers in the US and included a comparator cohort. Men with post-RP prostate-specific antigen greater than 0.03 ng/mL or adverse pathologic features were included. Data were collected from February 2018 to March 2021, and data were analyzed from January to October 2024. INTERVENTIONS: SBRT delivered at 30 to 34 Gy in 5 fractions to the prostate bed. Nodal irradiation, boost to gross disease, and/or hormonal therapy were delivered per physician discretion. MAIN OUTCOMES AND MEASURES: Late toxic effects (more than 90 days after treatment) were graded according to Common Terminology Criteria for Adverse Events version 4.03. PROs were measured using Expanded Prostate Cancer Index-26. The proportion of men whose PROs had decrements greater than twice the threshold for minimal clinically important difference (MCID) at any point during the first 2 years were evaluated. The longitudinal PROs for men receiving SBRT was compared with a cohort of 200 men receiving postoperative conventionally fractionated radiotherapy (CFRT) using logistic regression, while adjusting for baseline scores, age, and receipt of nodal irradiation. RESULTS: Of 100 patients treated with post-RP SBRT, the median (IQR) age was 68.5 (63.9-71.4) years, and the median (IQR) follow-up was 43 (37-53) months. Cumulative incidence of late grade 2 and 3 genitourinary toxic effects was 25% and 4%, respectively, and of late grade 2 and 3 gastrointestinal tract toxic effects was 3% and 3%, respectively. The proportion of patients with decrements more than 2-fold the MCID in PROs was 38.9% (37 of 95) for urinary incontinence, 17.9% (17 of 95) for urinary irritation, and 34.1% (31 of 91) for bowel function. Compared with the CFRT cohort, the adjusted odds ratio for patients receiving SBRT experiencing decrements more than 2-fold the MCID was 1.55 (95% CI, 0.87-2.76; P = .14) for urinary incontinence, 0.94 (95% CI, 0.46-1.94; P = .87) for urinary irritation, and 1.03 (95% CI, 0.57-1.84; P = .93) for bowel function. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, post-RP SBRT was well-tolerated, with no measurably different decline in urinary or bowel PROs through 2 years compared with CFRT. Randomized studies and longer follow-up will better define the toxic effects and efficacy profile of post-RP SBRT. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03541850.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Nikitas J, Ballas LK, Romero T, et al. Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 40372727. doi:10.1001/jamaoncol.2025.1059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。